PERIPHERAL T CELL LYMPHOMA
Clinical trials for PERIPHERAL T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control TerminatedThis study tested whether adding a drug called selinexor to standard chemotherapy or an immunotherapy drug (tislelizumab) could help control advanced T-cell and NK-cell lymphomas that had returned or stopped responding to prior treatments. It involved adults whose cancer had come…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo tested for Tough-to-Treat blood cancer
Disease control TerminatedThis early-stage study tested the safety and best dose of a two-drug combination (parsaclisib and chidamide) for adults with peripheral T-cell lymphoma that has come back or not responded to prior treatments. The main goals were to see how well patients tolerated the drugs and to…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC